Sökresultat - Jan Müller‐Brand

  • Visas 1 - 14 av 14 resultat
Förfina resultatet
  1. 1
    Plasma potassium in patients with terminal renal failure during and after haemodialysis; relationship with dialytic potassium removal and total body potassium

    Plasma potassium in patients with terminal renal failure during and after haemodialysis; relationship with dialytic potassium removal and total body potassium av A Blumberg, H.W. Roser, C Zehnder, Jan Müller‐Brand

    Publicerad 1997
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  2. 2
    The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease

    The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease av Martin A. Walter, R Melzer, Christian Schindler, Jan Müller‐Brand, Alan Tyndall, Egbert Nitzsche

    Publicerad 2005
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  3. 3
    The Dental Safety Profile of High-Dose Radioiodine Therapy for Thyroid Cancer: Long-Term Results of a Longitudinal Cohort Study

    The Dental Safety Profile of High-Dose Radioiodine Therapy for Thyroid Cancer: Long-Term Results of a Longitudinal Cohort Study av Martin A. Walter, Christian P. Turtschi, Christian Schindler, Peter Minnig, Jan Müller‐Brand, Beat P. Müller‐Stich

    Publicerad 2007
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  4. 4
    In vitro characterization of 177Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study

    In vitro characterization of 177Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study av Flavio Forrer, Jianhua Chen, Melpomeni Fani, P. Powell, Andreas Lohri, Jan Müller‐Brand, Gerhard Moldenhauer, Helmut R. Maëcke

    Publicerad 2009
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  5. 5
    Somatostatin Receptor–Targeted Radiopeptide Therapy with <sup>90</sup>Y-DOTATOC and <sup>177</sup>Lu-DOTATOC in Progressive Meningioma: Long-Term Results of a Phase II Clinical Trial

    Somatostatin Receptor–Targeted Radiopeptide Therapy with <sup>90</sup>Y-DOTATOC and <sup>177</sup>Lu-DOTATOC in Progressive Meningioma: Long-Term Results of a Phase II Clinical Tri... av Nicolas Marincek, Piotr Radojewski, Rebecca A. Dumont, Philippe Brunner, Jan Müller‐Brand, Helmut R. Maëcke, Matthias Briel, Martin A. Walter

    Publicerad 2015
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  6. 6
    Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial

    Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial av Dominik Cordier, Flavio Forrer, Frank Bruchertseifer, Alfred Morgenstern, Christos Apostolidis, Stephan Good, Jan Müller‐Brand, Helmut R. Mäcke, J.C. Reubi, Adrian Merlo

    Publicerad 2010
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  7. 7
    Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials

    Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials av Martin A. Walter, Matthias Briel, Mirjam Christ‐Crain, Steen Joop Bonnema, John Connell, David S. Cooper, Heiner C. Bucher, Jan Müller‐Brand, Beat P. Müller‐Stich

    Publicerad 2007
    Hämta fulltext Hämta fulltext
    Revisão
    Lägg till i favoriter
    Sparad:
  8. 8
    Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours

    Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours av Anna Romer, Daniela Seiler, Nicolas Marincek, Philippe Brunner, Michael Koller, Quinn K.T. Ng, Helmut R. Maëcke, Jan Müller‐Brand, Christoph Rochlitz, Matthias Briel, Christian Schindler, Martin A. Walter

    Publicerad 2013
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  9. 9
    Cohort Study of Somatostatin-Based Radiopeptide Therapy With [<sup>90</sup>Y-DOTA]-TOC Versus [<sup>90</sup>Y-DOTA]-TOC Plus [<sup>177</sup>Lu-DOTA]-TOC in Neuroendocrine Cancers

    Cohort Study of Somatostatin-Based Radiopeptide Therapy With [<sup>90</sup>Y-DOTA]-TOC Versus [<sup>90</sup>Y-DOTA]-TOC Plus [<sup>177</sup>Lu-DOTA]-TOC in Neuroendocrine Cancers av Linda Villard, Anna Romer, Nicolas Marincek, Philippe Brunner, Michael Koller, Christian Schindler, Quinn K.T. Ng, Helmut R. Mäcke, Jan Müller‐Brand, Christoph Rochlitz, Matthias Briel, Martin A. Walter

    Publicerad 2012
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  10. 10
    Progression to Overt or Silent CAD in Asymptomatic Patients With Diabetes Mellitus at High Coronary Risk

    Progression to Overt or Silent CAD in Asymptomatic Patients With Diabetes Mellitus at High Coronary Risk av Michael J. Zellweger, Michael Maraun, Hans H. Osterhues, Ulrich Keller, Jan Müller‐Brand, Raban Jeger, Otmar Pfister, Thilo Burkard, Friedrich Eckstein, Stefanie von Felten, Stefan Osswald, Matthias Pfisterer

    Publicerad 2014
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  11. 11
    Procalcitonin levels predict clinical course and progression‐free survival in patients with medullary thyroid cancer

    Procalcitonin levels predict clinical course and progression‐free survival in patients with medullary thyroid cancer av Martin A. Walter, Christian Meier, Tanja Radimerski, Fabienne Iten, Marius Kränzlin, Jan Müller‐Brand, Jan Willem B. de Groot, Ido P. Kema, Thera P. Links, Beat P. Müller‐Stich

    Publicerad 2009
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  12. 12
    Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors

    Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors av Nancy Sharma, Boris G. Naraev, Eric G. Engelman, M. Bridget Zimmerman, David Bushnell, Thomas M. O’Dorisio, M. Sue O’Dorisio, Yusuf Menda, Jan Müller‐Brand, James R. Howe, Þorvarður R. Hálfdánarson

    Publicerad 2016
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  13. 13
    The prognostic and predictive value of sstr2-immunohistochemistry and sstr2-targeted imaging in neuroendocrine tumors

    The prognostic and predictive value of sstr2-immunohistochemistry and sstr2-targeted imaging in neuroendocrine tumors av Philippe Brunner, Ann-Catherine Jörg, Katharina Glatz, Lukas Bubendorf, Piotr Radojewski, M Umlauft, Nicolas Marincek, Petar-Marko Spanjol, Thomas Krause, Rebecca A. Dumont, Helmut R. Maëcke, Jan Müller‐Brand, Matthias Briel, Anja Schmitt, Aurel Perren, Martin A. Walter

    Publicerad 2016
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  14. 14
    The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis

    The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis av Martin Fuchs, Matthias Briel, Thomas Daikeler, Ulrich A. Walker, Helmut Rasch, Scott Berg, Quinn K.T. Ng, Heike Raatz, David Jayne, Ina Kötter, Daniël Blockmans, María C. Cid, Sergio Prieto‐González, Peter Lamprecht, Carlo Salvarani, Zaharenia Th. Karageorgaki, Richard A. Watts, Raashid Luqmani, Jan Müller‐Brand, Alan Tyndall, Martin A. Walter

    Publicerad 2011
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:

Sökverktyg: